ABIONYX Pharma announces its cash position and provides an update on the activity for the 3rd quarter of 2022
• Continuation of the concentration of the Services activity on preclinical studies of Biotech in ophthalmology
• Ongoing determination of the strategic axes of clinical development in ophthalmology
• Cash of €3.8 million (excluding CIR) as of September 30, 2022
Toulouse, FRANCE, Lakeland, UNITED STATES, November 17, 2022, 6:30 p.m. CET – ABIONYX Pharma, (FR0012616852 – ABNX – PEA PME eligible), a next-generation biotech company dedicated to the discovery and development of innovative therapies, announces its position as cash for the 3rd quarter ended September 30, 2022 and reviews the highlights of the period.